TFF Pharmaceuticals (NASDAQ:TFFP – Get Rating) issued its earnings results on Wednesday. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.05, MarketWatch Earnings reports. TFF Pharmaceuticals had a negative return on equity of 61.58% and a negative net margin of 35,272.73%. During the same period in the previous year, the company posted ($0.33) earnings per share.
NASDAQ TFFP traded up $0.13 during mid-day trading on Thursday, reaching $4.12. The stock had a trading volume of 191,191 shares, compared to its average volume of 155,825. TFF Pharmaceuticals has a 1 year low of $3.60 and a 1 year high of $12.28. The stock has a market cap of $104.53 million, a PE ratio of -3.30 and a beta of 2.14. The company has a fifty day moving average price of $5.94 and a 200 day moving average price of $6.79.
In other news, Director Aaron G.L. Fletcher acquired 542,000 shares of TFF Pharmaceuticals stock in a transaction that occurred on Monday, April 4th. The shares were bought at an average cost of $6.47 per share, with a total value of $3,506,740.00. Following the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $647,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 9.90% of the company’s stock.
TFFP has been the subject of several research analyst reports. Zacks Investment Research cut TFF Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 30th. B. Riley reduced their price objective on TFF Pharmaceuticals from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, March 29th.
TFF Pharmaceuticals Company Profile (Get Rating)
TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.
- Get a free copy of the StockNews.com research report on TFF Pharmaceuticals (TFFP)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.